Literature DB >> 22613669

Functional genetic polymorphisms from phase-II drug metabolizing enzymes.

Sandeep Grover, Ritushree Kukreti.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22613669      PMCID： PMC6493454          DOI： 10.1111/j.1755-5949.2012.00343.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN： 1755-5930            Impact factor:   5.243


× No keyword cloud information.
  7 in total

1.  Human acetyltransferase polymorphisms.

Authors:  D M Grant; N C Hughes; S A Janezic; G H Goodfellow; H J Chen; A Gaedigk; V L Yu; R Grewal
Journal:  Mutat Res       Date:  1997-05-12       Impact factor: 2.433

2.  Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease.

Authors:  Ehtesham Arif; Arpana Vibhuti; Pervez Alam; Desh Deepak; Bhawani Singh; Mohammad Athar; M A Qadar Pasha
Journal:  Clin Chim Acta       Date:  2007-03-24       Impact factor: 3.786

3.  Genetic landscape of the people of India: a canvas for disease gene exploration.

Authors: 
Journal:  J Genet       Date:  2008-04       Impact factor: 1.166

4.  Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity.

Authors:  M Murali; T Manjari; B Madhuri; S Raghavan; D C Jain; S Vivekanandhan
Journal:  CNS Neurosci Ther       Date:  2012-01-24       Impact factor: 5.243

5.  Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization.

Authors:  Chin-Chuan Hung; Wei-Lun Chang; Jia-Ling Ho; John Jen Tai; Tsung-Jen Hsieh; Hsiao-Ching Huang; Yow-Wen Hsieh; Horng-Huei Liou
Journal:  Pharmacogenomics       Date:  2011-12-21       Impact factor: 2.533

6.  Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.

Authors:  Sandeep Grover; Mandaville Gourie-Devi; Ruchi Baghel; Sangeeta Sharma; Kiran Bala; Meena Gupta; Krishnamoorthy Narayanasamy; Binuja Varma; Meenal Gupta; Kavita Kaur; Puneet Talwar; Harpreet Kaur; Sudheer Giddaluru; Abhay Sharma; Samir K Brahmachari; Ritushree Kukreti
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

7.  Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogenetics.

Authors:  Sandeep Grover; Meenal Gupta; Ritushree Kukreti
Journal:  Indian J Hum Genet       Date:  2011-05
  7 in total
  3 in total

1.  Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.

Authors:  Vineetha Koroth Edavana; Rosalind B Penney; Aiwei Yao-Borengasser; Athena Starlard-Davenport; Ishwori B Dhakal; Susan Kadlubar
Journal:  Int J Cancer Res Mol Mech       Date:  2015-09-22

Review 2.  Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.

Authors:  Sarah C Preissner; Michael F Hoffmann; Robert Preissner; Mathias Dunkel; Andreas Gewiess; Saskia Preissner
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

Review 3.  Metabolomics in Autoimmune Diseases: Focus on Rheumatoid Arthritis, Systemic Lupus Erythematous, and Multiple Sclerosis.

Authors:  Naeun Yoon; Ah-Kyung Jang; Yerim Seo; Byung Hwa Jung
Journal:  Metabolites       Date:  2021-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.